| Autor: |
Li, Mei-xuan, Li, Yan-fei, Xing, Xin, Niu, Jun-qiang, Yao, Liang, Lu, Meng-ying, Guo, Ke, Ma, Mi-na, Wu, Xiao-tian, Ma, Ning, Li, Dan, Li, Zi-jun, Guan, Ling, Wang, Xiao-man, Pan, Bei, Shang, Wen-ru, Ji, Jing, Song, Zhong-yang, Zhang, Zhi-ming, Wang, Yong-feng |
| Předmět: |
|
| Zdroj: |
Inflammopharmacology; Feb2024, Vol. 32 Issue 1, p335-354, 20p |
| Abstrakt: |
Background: The clinical efficacy and safety of intravenous immunoglobulin (IVIg) treatment for COVID-19 remain controversial. This study aimed to map the current status and gaps of available evidence, and conduct a meta-analysis to further investigate the benefit of IVIg in COVID-19 patients. Methods: Electronic databases were searched for systematic reviews/meta-analyses (SR/MAs), primary studies with control groups, reporting on the use of IVIg in patients with COVID-19. A random-effects meta-analysis with subgroup analyses regarding study design and patient disease severity was performed. Our outcomes of interest determined by the evidence mapping, were mortality, length of hospitalization (days), length of intensive care unit (ICU) stay (days), number of patients requiring mechanical ventilation, and adverse events. Results: We included 34 studies (12 SR/MAs, 8 prospective and 14 retrospective studies). A total of 5571 hospitalized patients were involved in 22 primary studies. Random-effects meta-analyses of very low to moderate evidence showed that there was little or no difference between IVIg and standard care or placebo in reducing mortality (relative risk [RR] 0.91; 95% CI 0.78–1.06; risk difference [RD] 3.3% fewer), length of hospital (mean difference [MD] 0.37; 95% CI − 2.56, 3.31) and ICU (MD 0.36; 95% CI − 0.81, 1.53) stays, mechanical ventilation use (RR 0.92; 95% CI 0.68–1.24; RD 2.8% fewer), and adverse events (RR 0.98; 95% CI 0.84–1.14; RD 0.5% fewer) of patients with COVID-19. Sensitivity analysis using a fixed-effects model indicated that IVIg may reduce mortality (RR 0.76; 95% CI 0.60–0.97), and increase length of hospital stay (MD 0.68; 95% CI 0.09–1.28). Conclusion: Very low to moderate certainty of evidence indicated IVIg may not improve the clinical outcomes of hospitalized patients with COVID-19. Given the discrepancy between the random- and fixed-effects model results, further large-scale and well-designed RCTs are warranted. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink